This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term care facilities, and medical equipment and supplies. Companies in this sector include Astra Zeneca, Pfizer and Roche Holding.
BB Biotech (SWX:BION) showed a resilient investment performance in an extremely difficult period for biotech in the first quarter this year, although its NAV, share price and long standing premium have all clearly come under pressure. The Swiss investment company closed the first quarter of 2022 with its shares trading at CHF65.4, down by 10.3%, […]
In QuotedData’s morning briefing 11 March 2022: CQS Natural Resources Growth and Income (CYN) has announced its interim results for the six months ended 31 December 2021. CYN’s chairman, Richard Prickett says that, during the period, commodity markets were strong and interestingly for the sector higher interest rate expectations are supporting a broad market rotation […]
RTW makes two investments: Magnolia Medical Technologies RTW says that Magnolia Medical Technologies has completed a $46m growth equity financing round. The company, alongside other investment vehicles of RTW Investments, LP, participated in the financing round together with other investors. Magnolia Medical is a privately held medical technology company that develops, manufactures, and markets innovative […]
With valuations in biotech having fallen substantially in the last year, BB Biotech (SWX: BION) sees compelling opportunities in the small-to-mid cap space this year and believes some of its core portfolio companies, such as Neurocrine, Incyte and Ionis Pharmaceuticals, could see interest from strategic investors, including as M&A targets. The comments come in the […]
BB Biotech (SWX: BION) seems to be resilient in the current challenging period for biotech investing and most especially in the last week, which ranks as one of the most important trading periods in the biotech calendar. The Swiss investment company saw a 0.8% fall in its NAV in the five days from January 10-14th […]
Swiss investment company BB Biotech (SWX:BION) closed 2021 with its shares trading at CHF77.15, a rise by 8.3% over the year. However, the positive stock performance contrasts with an 11.4% fall in its NAV to CHF59.4/share in 2021, which was adversely affected by the severe bear market for biotech – and particularly its small to […]
Polar Capital Global Healthcare (PCGH) has released its annual results for the year ended 30 September 2021, during which it has provided NAV and share price total returns of 19.46% and 24.55%, strongly outperforming its benchmark, the MSCI ACWI Health Care Index, which returned 13.40%. Since its restructuring to 30 September 2021, PCGH has provided […]
Syncona’s Anaveon secures Series B financing – Syncona has committed CHF35m (£29m) to Anaveon AG as part of a CHF110m (£90m) Series B financing round. Syncona was a cornerstone investor. The financing round was led by Forbion and supported by a leading international syndicate of specialist investors, including existing investor Novartis Venture Fund and new investors […]
Syncona backs launch of Clade Therapeutics – Syncona was the lead investor in the $87m Series A financing of Clade Therapeutics, a new cell therapy company. Syncona’s commitment was $30m and the first tranche of that – $15.0m – has been invested already. Syncona’s stake in the company is 22.6% (assuming all commitments are invested). […]
BB Biotech has disclosed an increase in its holding in Mersana Therapeutics (Nasdaq:NRSN), the timing of which suggests it again aims to capitalise on a 40% fall in an investee company’s share price that occurred after a clinical trial update earlier in the month. The Swiss investment company disclosed the increased holding in a SEC […]
In QuotedData’s morning briefing 10 September 2021: RTW Venture (RTW) has announced a new portfolio investment in Lycia Therapeutics, following its participation in the company’s US$70m series B financing round, the proceeds of which are intended to advance Lycia’s discovery pipeline of LYTAC degraders. Lycia is a privately held biotechnology company developing extracellular protein degradation […]
Swiss investor BB Biotech’s (SWX:BION) large position in US covid vaccine producer Moderna continues to drive a remarkable performance in a volatile US biotech market. Yesterday, Moderna (Nasdaq: MRNA) surged 17% to a new all-time high of $484.5/share, giving it a market capitalisation of $167bn. Moderna is the largest of BB Biotech’s holdings accounting for […]
BB Biotech’s (SWX:BION) large position in US covid vaccine producer Moderna drove a strong performance against a volatile US biotech market in the first half of this year. Moderna was the second best performer within BB Biotech’s portfolio during the period, with a rise of 105%, beaten only by Essa Pharmaceuticals, whose stock was up […]
Essa Pharmaceutials (Nasdaq: EPIX) and Moderna (MRNA) may have been the top performers within Swiss investment company BB Biotech’s (SIX:BION) 34-strong portfolio in the first half, sporting stock price rises of 137% and 124% respectively, but these gains are modest by comparison with some of the ones from within the wider world of biotech investing. […]
BB Biotech (SWX:BION) ended the first half with its shares up 22.2% and at CHF87 at the close yesterday, just 5% below their all-time high of CHF90 that was reached in February. The Swiss investment company’s net asset value grew by 8.9% in the first half to CHF73.1 per share, which seems to be a […]
RTW backs Umoja Biopharma – Umoja Biopharma, Inc. has just completed a $210m Series B financing round. RTW Venture Fund participated in the financing round together with other investment firms, including other investment vehicles of RTW Investments, LP. Umoja is a US-based privately held oncology company. It is using a new approach to immunotherapy, reprogramming immune cells directly […]
BB Biotech (SWX:BION) increased its stake in the US cancer biotech MacroGenics by a fifth just over a week ago, seemingly taking advantage of a fall in the company’s share price in the wake of the ASCO scientific meeting earlier this month. Hitherto, MacroGenics ranked in tenth position in BB Biotech’s portfolio, accounting for 3.6% […]
BB Biotech’s large bet on the US regulatory approval of Biogen’s Alzheimer’s disease therapy aducanumab has met with success, after the FDA rendered an approval in a landmark, although highly controversial, decision yesterday. The news prompted a huge rise in Biogen’s share price (Nasdaq: BIIB), which closed 38% up at $395/share, having peaked at $450 […]
Two of BB Biotech’s holdings were among the largest movers – one up and one down – on Friday, the first day of ASCO – the American Society of Clinical Oncology – when stocks responded to an avalanche of updated clinical trial data released at the start of the virtual scientific meeting. Fate Therapeutics, BB […]
A 2020 vintage investment for Switzerland’s BB Biotech has turned out to be one of the highest profile victims of the stock price moves occasioned by the ASCO abstract release earlier this week. Black Diamond Therapeutics (Nasdaq: BDTX) saw its shares fall by 37% yesterday after early-stage results of its lead compound BDTX-189 – although […]
In QuotedData’s morning briefing 7 May 2021: Shareholders have approved both a change of name and a revised investment Policy for Jupiter US Smaller Companies (JUS), which reflects the change of investment manager to US based Brown Advisory (click here to read our initiation note on the company which takes a detailed look at Brown’s […]
Shares in the US Covid vaccine developer Moderna – the second largest holding for giant Swiss investment company BB Biotech – fell by 6% yesterday, after the Biden Administration said it would support an exceptional waiver of IP protection on COVID-19 vaccines for developing countries through the World Trade Organisation. Moderna accounted for 7.8% of […]
Swiss investor BB Biotech made two new investments in the first quarter in US small caps – Essa Pharma and Revolution Medicines – while exiting its positions in Cidara Therapeutics and Voyager Therapeutics, according to its portfolio update published earlier today. Essa Pharma (Nasdaq: EPIX) is developing a small molecule drug, EPI-7386, in metastatic castration-resistant […]
Schroder British Opportunities (SBO) has announced an investment into Cera Care Limited, as part of a new funding round to support the company’s growth plans, in a transaction led by Evolve HealthCare Partners, a pan-European healthcare focused private equity firm. Cera is a technology-enabled home care provider founded and based in the UK. The new […]
BB Biotech ends a turbulent first quarter in good health BB Biotech posted a respectable performance in the first quarter of 2021, in a period that proved to be quite turbulent for biotech stocks. As of 31 March, BB Biotech stock closed at CHF82.20, up 15.4% year to date, while the NAV was CHF70.75/share, up […]
RTW backs Pyxis Oncology – RTW Venture Fund Limited has highlighted an announcement by Pyxis Oncology, Inc. On 30 March 2021 that company completed a $152 million Series B financing round, which was co-led by RTW Investments, LP. The company, alongside other investment vehicles of the Investment Manager, confirms that it participated in the financing round together with […]
BB Biotech top pick Ionis hit by safety setback – BB Biotech’s top holding, US antisense therapeutics pioneer Ionis Pharmaceuticals, has suffered a material setback, after the independent committee monitoring trials of one of its lead development products – tominersen, which is partnered with the pharma giant Roche – recommended discontinuation of dosing in Phase III […]
Biopharma Credit looking healthy – BioPharma Credit has published its annual report for the period ended 31 December 2020. Highlights are: NAV was fairly flat during the period, decreasing by $0.018 from $1.0217 to $1.0037 8.29 cents per share in total dividends during period, comfortably ahead of the target to distribute at least 7 cents per […]
Syncona backs Quell financing – Syncona Ltd has made a new £25.3m commitment to a £61.0m expanded Series A financing for Quell Therapeutics. This is the largest amount of funding to date for any stand-alone engineered T regulatory cell (Treg) company [see below] and takes Syncona’s total commitment to this business to £59.3m (of which £35.1m […]
Achilles Therapeutics, a Syncona portfolio company, has announced that an Independent Data and Safety Monitoring Committee (IDSMC) has completed its first review of the ongoing, first-in-human Phase I/II CHIRON and THETIS trials and has recommended that both clinical trials continue as planned. Achilles Therapeutics is a clinical-stage biopharmaceutical company developing precision T cell therapies to […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated